Biocryst Pharmaceuticals (BCRX) Amortization of Deferred Charges (2011 - 2020)

Biocryst Pharmaceuticals (BCRX) has 10 years of Amortization of Deferred Charges data on file, last reported at $1.4 million in Q4 2020.

• Quarterly Amortization of Deferred Charges rose 299.71% year-over-year to $1.4 million in Q4 2020, while the trailing twelve-month figure through Dec 2020 was $2.4 million (up 90.07% YoY) and the FY2020 annual result came in at $2.4 million, up 89.98% from the prior year.
• Amortization of Deferred Charges rose to $1.4 million in Q4 2020, from $381000.0 in the prior quarter.
• In the past five years, Amortization of Deferred Charges ranged from a high of $1.4 million in Q4 2020 to a low of $110000.0 in Q1 2016.
• A 5-year average of $299473.7 and a median of $223000.0 in 2016 frame the typical range for Amortization of Deferred Charges.
• Annual changes were most pronounced in 2018 — Amortization of Deferred Charges declined 4.13% — and 2020, when it surged 299.71%.
• Tracing BCRX's Amortization of Deferred Charges over 5 years: stood at $223000.0 in 2016, then retreated by 2.24% to $218000.0 in 2017, then dropped by 4.13% to $209000.0 in 2018, then jumped by 63.64% to $342000.0 in 2019, then surged by 299.71% to $1.4 million in 2020.
• The last three Amortization of Deferred Charges figures came in at $1.4 million (Q4 2020), $381000.0 (Q3 2020), and $341000.0 (Q1 2020), per Business Quant data.